Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Update

Key Points

• Bavarian Nordic experienced a 100% increase in short interest in July, with the total reaching 200 shares by the end of the month.
• The stock traded at $12.37 as of the latest market data, having a market capitalization of $2.93 billion and a PE ratio of 15.46.
• The company specializes in developing and commercializing life-saving vaccines, including those for smallpox, monkeypox, and Ebola.

Bavarian Nordic (OTCMKTS:BVNRY - ) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 200 shares, anincreaseof100.0% from the July 15th total of 100 shares. Based on an average daily volume of 38,100 shares, the short-interest ratio is presently 0.0 days. Currently,0.0% of the shares of the stock are sold short. Currently,0.0% of the shares of the stock are sold short. Based on an average daily volume of 38,100 shares, the short-interest ratio is presently 0.0 days.

Bavarian Nordic Price Performance

OTCMKTS BVNRY traded down $0.01 during trading hours on Friday, hitting $12.37. 2,798 shares of the company's stock traded hands, compared to its average volume of 16,073. Bavarian Nordic has a 52-week low of $6.60 and a 52-week high of $14.60. The company has a market capitalization of $2.93 billion, a PE ratio of 15.46 and a beta of 1.36. The firm's 50-day moving average is $10.20 and its 200-day moving average is $8.74.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.